Aldevron will supply $GNPX Tumor Suppressor Candidate2 plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer.

Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. https://finance.yahoo.com/news/genprex-taps-a...00040.html